Emerging Evidence of a More Complex Role for Proinflammatory and Antiinflammatory Cytokines in the Sepsis Response

[1]  L. Moldawer,et al.  Discordant tumor necrosis factor-alpha superfamily gene expression in bacterial peritonitis and endotoxemic shock. , 1999, Surgery.

[2]  R. Hotchkiss,et al.  Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. , 1999, Critical care medicine.

[3]  L. Moldawer,et al.  Caspase-3-dependent organ apoptosis early after burn injury. , 1999, Annals of surgery.

[4]  I. Chaudry,et al.  Splenic immune suppression in sepsis: A role for IL-10-induced changes in P38 MAPK signaling. , 1999, The Journal of surgical research.

[5]  S. Korsmeyer,et al.  Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. , 1999, Journal of immunology.

[6]  T. Standiford,et al.  IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. , 1999, Journal of immunology.

[7]  S. Streat,et al.  Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. , 1998, Critical care medicine.

[8]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[9]  E. Keystone,et al.  IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. , 1998, Rheumatic diseases clinics of North America.

[10]  L. Moldawer,et al.  Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. , 1998, Archives of surgery.

[11]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[12]  L. Moldawer,et al.  Disparate Roles for TNF-α and Fas Ligand in Concanavalin A-Induced Hepatitis , 1998, The Journal of Immunology.

[13]  L. Moldawer,et al.  Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. , 1998, Journal of applied physiology.

[14]  J. Vincent.  Search for effective immunomodulating strategies against sepsis , 1998, The Lancet.

[15]  R. Westendorp,et al.  Anti-inflammatory cytokine profile and mortality in febrile patients , 1998, The Lancet.

[16]  R. McIntyre,et al.  The physiologic basis for anticytokine clinical trials in the treatment of sepsis. , 1998, Journal of the American College of Surgeons.

[17]  I. Chaudry,et al.  Increased mucosal B-lymphocyte apoptosis during polymicrobial sepsis is a Fas ligand but not an endotoxin-mediated process. , 1998, Blood.

[18]  R. Sékaly,et al.  Specific Activation of the Cysteine Protease CPP32 during the Negative Selection of T Cells in the Thymus , 1997, The Journal of experimental medicine.

[19]  George Kollias,et al.  In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis , 1997, European journal of immunology.

[20]  G. Kollias,et al.  A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling , 1997, European journal of immunology.

[21]  J. Lederer,et al.  Anti-interleukin-10 antibody restores burn-induced defects in T-cell function. , 1997, Surgery.

[22]  R. Hotchkiss,et al.  Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. , 1997, Critical care medicine.

[23]  A. Baue.  Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? , 1997, Archives of surgery.

[24]  L. Moldawer,et al.  Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. , 1997, Journal of vascular surgery.

[25]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[26]  L. Moldawer,et al.  A MATRIX METALLOPROTEINASE INHIBITOR PREVENTS PROCESSING OF TUMOR NECROSIS FACTOR α (TNFα) AND ABROGATES ENDOTOXIN‐INDUCED LETHALITY , 1997 .

[27]  L. Moldawer,et al.  Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. , 1997, The Journal of surgical research.

[28]  E. Reinherz,et al.  T‐cell receptor ligation by peptide/MHC induces activation of a caspase in immature thymocytes: the molecular basis of negative selection , 1997, The EMBO journal.

[29]  U. Steckholzer,et al.  Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. , 1997, The Journal of trauma.

[30]  S. Nagata,et al.  Essential roles of the Fas ligand in the development of hepatitis , 1997, Nature Medicine.

[31]  T. Gotoh,et al.  DNA fragmentation is not the primary event in glucocorticoid‐induced thymocyte death in vivo , 1997, European journal of immunology.

[32]  R. Hotchkiss,et al.  CECAL LIGATION AND PUNCTURE (CLP) INDUCES APOPTOSIS IN THYMUS, SPLEEN, LUNG, AND GUT BY AN ENDOTOXIN AND TNF‐INDEPENDENT PATHWAY , 1997, Shock.

[33]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[34]  T. van der Poll,et al.  Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. , 1997, Journal of immunology.

[35]  J. Vauthey,et al.  Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. , 1997, Journal of immunology.

[36]  T. van der Poll,et al.  Interleukin-10 impairs host defense in murine pneumococcal pneumonia. , 1996, The Journal of infectious diseases.

[37]  R. Bone,et al.  Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS) , 1996, Annals of Internal Medicine.

[38]  T. van der Poll,et al.  Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. , 1996, Blood.

[39]  J. Vauthey,et al.  A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon , 1996, The Journal of experimental medicine.

[40]  R. Bone,et al.  Sir Isaac Newton, sepsis, SIRS, and CARS. , 1996, Critical care medicine.

[41]  I. Chaudry,et al.  Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. , 1996, Blood.

[42]  M. Cuesta,et al.  Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. , 1996, Blood.

[43]  I. Chaudry,et al.  Is sepsis-induced apoptosis associated with macrophage dysfunction? , 1996, The Journal of trauma.

[44]  S. Calvano,et al.  Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. , 1996, Journal of immunology.

[45]  E. Radwanski,et al.  Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. , 1996, Blood.

[46]  M. Ueffing,et al.  Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. , 1995, Blood.

[47]  T. van der Poll,et al.  Endogenous IL-10 protects mice from death during septic peritonitis. , 1995, Journal of immunology.

[48]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[49]  T. Standiford,et al.  Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. , 1995, Journal of immunology.

[50]  L. Moldawer,et al.  BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE , 1995, Shock.

[51]  P. Krammer,et al.  Regulation of cell surface APO‐1/Fas (CD95) ligand expression by metalloproteases , 1995, European journal of immunology.

[52]  M. Burdick,et al.  Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. , 1995, The Journal of clinical investigation.

[53]  L. Shapiro,et al.  A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. , 1995, Journal of immunology.

[54]  S. Calvano,et al.  Influence of IL-1 receptor blockade on the human response to endotoxemia. , 1995, Journal of immunology.

[55]  M. Leist,et al.  Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. , 1995, Journal of immunology.

[56]  T. van der Poll,et al.  Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees , 1994, The Journal of experimental medicine.

[57]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[58]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[59]  F. Calzetti,et al.  Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation , 1994, The Journal of experimental medicine.

[60]  M. Billah,et al.  Interleukin-10 inhibits interleukin-8 production in human neutrophils. , 1994, Blood.

[61]  S. Calvano,et al.  A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon , 1994, The Journal of experimental medicine.

[62]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[63]  T. van der Poll,et al.  Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. , 1994, The Journal of infectious diseases.

[64]  C. Wanidworanun,et al.  Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. , 1993, Journal of immunology.

[65]  G. Constantin,et al.  Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide , 1993, The Journal of experimental medicine.

[66]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[67]  M. Howard,et al.  Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.

[68]  W. Fiers,et al.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.

[69]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[70]  L. Moldawer,et al.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. , 1992, Blood.

[71]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[72]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[73]  C. Figdor,et al.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression , 1991, The Journal of experimental medicine.

[74]  H. Büller,et al.  Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans , 1991 .

[75]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[76]  B. Echtenacher,et al.  Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.

[77]  A C Allison,et al.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. , 1990, The Journal of clinical investigation.

[78]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[79]  C. Perez,et al.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF , 1988, Cell.

[80]  J. D. Albert,et al.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.

[81]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[82]  D. Goeddel,et al.  Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[83]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[84]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[85]  G. Kollias,et al.  Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. , 1996, Journal of inflammation.

[86]  M. Goldman,et al.  High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. , 1995, The Journal of infectious diseases.

[87]  J. J. Thompson,et al.  Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. , 1991, The Journal of infectious diseases.

[88]  L. Moldawer,et al.  Identification of a novel tumor necrosis factor alpha/cachectin from the livers of burned and infected rats. , 1990, Archives of surgery.

[89]  A. C. Webb,et al.  Human and murine interleukin 1 possess sequence and structural similarities. , 1985, The Journal of molecular and cellular immunology : JMCI.

[90]  P. Lomedico,et al.  Cloning and expression of murine interleukin-1 cDNA in Escherichia coli , 1984, Nature.

[91]  L. Camoglio,et al.  Immunotherapy of Crohn's disease. , 1998, Mediators of inflammation.